Stem Cells:  From Lab to Patients

Bradley J. Fikes
Bio-technology Reporter
San Diego Union-Tribune

Stem cell-based therapy is at last moving into mainstream medicine, after many years of hype and hope. But there’s also fear that this therapy has been exaggerated by the numerous clinics that promise startling improvement to patients who pay large sums for treatment. What kinds of stem cell therapy are really legitimate and which are dubious? And how can people know the difference? Bradley Fikes, the San Diego Union-Tribune’s biotech reporter, gives his perspectives on this important industry.

The text of Mr. Fikes’s presentation can be found at the following link:

Stem Cells:  From Lab to Patients